Atorvastatin exhibits anticancer effects by inhibiting YAP/TAZ activity in mesenchymal-like non-small cell lung cancer
Abstract Non-small cell lung cancer (NSCLC) accounts for most lung cancer diagnoses. Statins preferentially inhibit the proliferation of mesenchymal- over epithelial-like cells in various types of cancer, including NSCLCs. However, the mechanisms underlying the differential statin sensitivity of mes...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-15624-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849735906950381568 |
|---|---|
| author | Takuro Ishikawa Tomohito Okubo Natsuki Matsushita Jiro Tashiro Katsuhiko Warita Munekazu Naito |
| author_facet | Takuro Ishikawa Tomohito Okubo Natsuki Matsushita Jiro Tashiro Katsuhiko Warita Munekazu Naito |
| author_sort | Takuro Ishikawa |
| collection | DOAJ |
| description | Abstract Non-small cell lung cancer (NSCLC) accounts for most lung cancer diagnoses. Statins preferentially inhibit the proliferation of mesenchymal- over epithelial-like cells in various types of cancer, including NSCLCs. However, the mechanisms underlying the differential statin sensitivity of mesenchymal and epithelial cancer cells remain unknown. Statins inhibit YAP/TAZ, effectors of the Hippo pathway, via depletion of geranylgeranyl pyrophosphate. Here, we aimed to elucidate the mechanisms underlying statin sensitivity in mesenchymal cancer. We explored the anticancer effects of atorvastatin and its association with YAP/TAZ activity in NSCLC cell lines with different epithelial-mesenchymal phenotypes. Atorvastatin significantly reduced the proliferation, migration, and invasion of mesenchymal-like cells, while showing negligible effect on epithelial-like cells. Atorvastatin also inhibited YAP/TAZ nuclear localization and downstream gene expression in mesenchymal cells but did not affect epithelial cells. Small interfering (si) RNA-mediated inhibition of both YAP and TAZ reduced the proliferation of all NSCLC cell lines tested, regardless of phenotype, indicating that sensitivity to YAP/TAZ inhibition and statins differ. In summary, our results suggest that inhibited YAP/TAZ nuclear localization by statins differs between epithelial and mesenchymal NSCLC cell lines, resulting in differential statin sensitivity. |
| format | Article |
| id | doaj-art-b807742129fe4d249267313d062fdfef |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-b807742129fe4d249267313d062fdfef2025-08-20T03:07:26ZengNature PortfolioScientific Reports2045-23222025-08-0115111310.1038/s41598-025-15624-2Atorvastatin exhibits anticancer effects by inhibiting YAP/TAZ activity in mesenchymal-like non-small cell lung cancerTakuro Ishikawa0Tomohito Okubo1Natsuki Matsushita2Jiro Tashiro3Katsuhiko Warita4Munekazu Naito5Department of Veterinary Anatomy, School of Veterinary Medicine, Tottori UniversityDepartment of Anatomy, School of Medicine, Aichi Medical UniversityDivision of Laboratory Animal Research, School of Medicine, Aichi Medical UniversityDepartment of Veterinary Anatomy, School of Veterinary Medicine, Tottori UniversityDepartment of Veterinary Anatomy, School of Veterinary Medicine, Tottori UniversityDepartment of Anatomy, School of Medicine, Aichi Medical UniversityAbstract Non-small cell lung cancer (NSCLC) accounts for most lung cancer diagnoses. Statins preferentially inhibit the proliferation of mesenchymal- over epithelial-like cells in various types of cancer, including NSCLCs. However, the mechanisms underlying the differential statin sensitivity of mesenchymal and epithelial cancer cells remain unknown. Statins inhibit YAP/TAZ, effectors of the Hippo pathway, via depletion of geranylgeranyl pyrophosphate. Here, we aimed to elucidate the mechanisms underlying statin sensitivity in mesenchymal cancer. We explored the anticancer effects of atorvastatin and its association with YAP/TAZ activity in NSCLC cell lines with different epithelial-mesenchymal phenotypes. Atorvastatin significantly reduced the proliferation, migration, and invasion of mesenchymal-like cells, while showing negligible effect on epithelial-like cells. Atorvastatin also inhibited YAP/TAZ nuclear localization and downstream gene expression in mesenchymal cells but did not affect epithelial cells. Small interfering (si) RNA-mediated inhibition of both YAP and TAZ reduced the proliferation of all NSCLC cell lines tested, regardless of phenotype, indicating that sensitivity to YAP/TAZ inhibition and statins differ. In summary, our results suggest that inhibited YAP/TAZ nuclear localization by statins differs between epithelial and mesenchymal NSCLC cell lines, resulting in differential statin sensitivity.https://doi.org/10.1038/s41598-025-15624-2StatinsNon-small cell lung cancerYAPTAZMesenchymal cancer cells |
| spellingShingle | Takuro Ishikawa Tomohito Okubo Natsuki Matsushita Jiro Tashiro Katsuhiko Warita Munekazu Naito Atorvastatin exhibits anticancer effects by inhibiting YAP/TAZ activity in mesenchymal-like non-small cell lung cancer Scientific Reports Statins Non-small cell lung cancer YAP TAZ Mesenchymal cancer cells |
| title | Atorvastatin exhibits anticancer effects by inhibiting YAP/TAZ activity in mesenchymal-like non-small cell lung cancer |
| title_full | Atorvastatin exhibits anticancer effects by inhibiting YAP/TAZ activity in mesenchymal-like non-small cell lung cancer |
| title_fullStr | Atorvastatin exhibits anticancer effects by inhibiting YAP/TAZ activity in mesenchymal-like non-small cell lung cancer |
| title_full_unstemmed | Atorvastatin exhibits anticancer effects by inhibiting YAP/TAZ activity in mesenchymal-like non-small cell lung cancer |
| title_short | Atorvastatin exhibits anticancer effects by inhibiting YAP/TAZ activity in mesenchymal-like non-small cell lung cancer |
| title_sort | atorvastatin exhibits anticancer effects by inhibiting yap taz activity in mesenchymal like non small cell lung cancer |
| topic | Statins Non-small cell lung cancer YAP TAZ Mesenchymal cancer cells |
| url | https://doi.org/10.1038/s41598-025-15624-2 |
| work_keys_str_mv | AT takuroishikawa atorvastatinexhibitsanticancereffectsbyinhibitingyaptazactivityinmesenchymallikenonsmallcelllungcancer AT tomohitookubo atorvastatinexhibitsanticancereffectsbyinhibitingyaptazactivityinmesenchymallikenonsmallcelllungcancer AT natsukimatsushita atorvastatinexhibitsanticancereffectsbyinhibitingyaptazactivityinmesenchymallikenonsmallcelllungcancer AT jirotashiro atorvastatinexhibitsanticancereffectsbyinhibitingyaptazactivityinmesenchymallikenonsmallcelllungcancer AT katsuhikowarita atorvastatinexhibitsanticancereffectsbyinhibitingyaptazactivityinmesenchymallikenonsmallcelllungcancer AT munekazunaito atorvastatinexhibitsanticancereffectsbyinhibitingyaptazactivityinmesenchymallikenonsmallcelllungcancer |